Hansoh Pharma Partners with KiOmed Pharma in Belgium to Develop New Generation Innovative Products for Osteoarthritis

Hansoh Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Hansen Pharmaceutical") and Belgium KiOmed Pharma SA (hereinafter referred to as "KiOmed") jointly announced that the two parties have reached an agreement on the development of KiOmed's innovative product KiOmedinevsOne in mainland China, Macau and Taiwan. Registration and Commercialization Exclusive License Agreement.

According to the terms of the agreement, Hansoh Pharmaceuticals will obtain the exclusive rights of KiOmedinevsOne for the development, registration and commercialization of osteoarthritis-related indications in the authorized territory, and will pay an upfront payment and development, registration and sales-based commercialization milestones of up to 66 million Potential payments in Euros, plus double-digit tiered royalties on future net product sales.

KiOmedinevsOne is the world's first exclusive non-animal new generation of KiOmedine CM-Chitosan for the treatment of knee osteoarthritis single injection, KiOmedine CM-Chitosan is a highly purified polysaccharide derived from Agaricus bisporus (Enoki mushroom) , is a Belgian patented technology . Unlike hyaluronic acid, the standard treatment for osteoarthritis, KiOmedinevsOne has a dual mechanism of action that relieves discomfort and other symptoms of osteoarthritis by reducing oxidative stress and enhancing joint lubrication. Clinical studies have shown that after a single injection of KiOmedinevsOne, patients can observe significant pain relief within 2 weeks, the Osteoarthritis Index (WOMAC) pain score is reduced by 66%, and the relief of osteoarthritis symptoms can last for at least 6 months. KiOmedinevsOne has received CE certification and will be launched in Europe in 2021.

Osteoarthritis is a common disabling disease in clinical practice, affecting about 250 million people worldwide, and the prevalence of knee osteoarthritis accounts for about 85% of osteoarthritis. According to epidemiological surveys, the prevalence rate of knee osteoarthritis in my country is 8.1%, and women are much higher than men. As my country enters an aging society, the number of patients with osteoarthritis will increase significantly, and there is still a long-term lack of safe and effective treatment methods in clinical practice. KiOmedinevsOne is expected to further meet the huge unfinished clinical needs in my country.

Sun Yuan, executive director of Hansoh Pharmaceuticals, said: "KiOmed is a leader and expert in natural chitosan products, and we are very pleased to cooperate with KiOmed. Osteoarthritis seriously affects the quality of life of patients and brings heavy burdens to patients' families and society. We are pleased to see that KiOmedinevsOne has shown great potential in the field of osteoarthritis treatment, and the clinical treatment is convenient and effective, and we look forward to this differentiated innovative product to bring more meaningful clinical benefits to Chinese patients."

Francois Blondel, founder and executive chairman of KiOmed, said: "We are very pleased to cooperate with Hansoh Pharma, a leading innovation-driven pharmaceutical company in China, and KiOmedinevsOne has shown excellent long-acting treatment in the field of osteoarthritis treatment through validation in multiple regions in Europe and safety advantages. It is believed that with Hansoh’s mature development and commercialization experience in Greater China, KiOmedinevsOne can benefit the vast number of osteoarthritis patients in China as soon as possible.”